Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): Experience from the RESITRA-REIPI cohort

Transplant Infectious Disease

Volumn 16, Issue 3, 2014, Pages 387-396

  Meije, Y ^a   Fortun J ^b   Len, O ^a   Aguado, J M ^c   Moreno, A ^d   Cisneros, J M ^e   Gurgui M ^f   Carratala J ^d   Munoz P ^g   Montejo, M ^h   Blanes, M ⁱ   Bou, G ^j   Perez J L ^k   Torre Cisneros, J ^l   Ramos, A ^m   Pahissa, A ^a   Gavalda J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h HOSPITAL DE CRUCES   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j HOSPITAL JUAN CANALEJO   (Spain)

^k HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^l UNIVERSITY OF CÓRDOBA   (Spain)

^m HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

more..

Author keywords

Cytomegalovirus; Graft dysfunction; Preemptive therapy; Transplantation; Universal prophylaxis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; MYCOPHENOLIC ACID; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS LOAD; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; RISK FACTOR; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; VIRUS REPLICATION; YOUNG ADULT;

EID: 84901943834     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12226     Document Type: Article

References (39)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338 (24): 1741-1751.
2. Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007; 21 (2): 149-158.
3. Lumbreras C. Infección vírica en el receptor de un trasplante de hígado. In: Aguado JM, ed. Infecciones en Pacientes Trasplantados. Madrid: Harcourt, S.A., 2000: 323-345.
4. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12 (Suppl 7): S754-S766.
5. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365 (9477): 2105-2115.
6. Len O, Gavalda J, Aguado JM, et al. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis 2008; 46 (1): 20-27.
7. Metselaar HJ, van Campenhout MJ, van der Eijk AA. The best way to prevent cytomegalovirus infection after liver transplantation: the debate goes on. Transpl Int 2013; 26 (6): 590-591.
8. Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013; 2: CD005133.
9. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8 (5): 975-983.
10. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143 (12): 870-880.
11. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96 (4): 333-360.
12. de la Torre-Cisneros J, Farinas MC, Caston JJ, et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011; 29 (10): 735-758.
13. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005; 40 (5): 704-708.
14. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78 (9): 1390-1396.
15. Cervera C, Pineda M, Linares L, et al. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients. Transplant Proc 2007; 39 (7): 2228-2230.
16. Meylan PR, Manuel O. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr Opin Infect Dis 2007; 20 (4): 412-418.
17. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10 (5): 1228-1237.
18. Kalil AC, Sun J, Florescu DF. IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis. Am J Transplant 2011; 11 (1): 18-21.
19. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 2006; 35 (4): 474-477.
20. Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E, et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 2011; 91 (8): 927-933.
21. San Juan R, Aguado JM, Lumbreras C, et al. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007; 7 (4): 964-971.
22. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6 (2): 262-274.
23. Torre-Cisneros J, Fortun J, Aguado JM, et al. Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus infection in transplanted patients. Enferm Infecc Microbiol Clin 2005; 23 (7): 424-437.
24. Bodro M, Sabe N, Llado L, et al. Prophylaxis vs. preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. Liver Transpl 2012; 18 (9): 1093-1099.
25. Manuel O, Kralidis G, Mueller NJ, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2013; 13 (9): 2402-2410.
26. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6 (9): 2134-2143.
27. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43 (7): 869-880.
28. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8 (1): 69-77.
29. Onor IO, Todd SB, Meredith E, et al. Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Transpl Int 2013; 26 (6): 592-600.
30. Singh N. Unraveling the biologic basis of late-onset cytomegalovirus disease in high-risk organ transplant recipients. Transplantation 2011; 91 (8): 825-826.
31. Hoppe L, Marroni CA, Bressane R, et al. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients. Transplant Proc 2006; 38 (6): 1922-1923.
32. San Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47 (7): 875-882.
33. Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59 (6): 851-859.
34. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008; 8 (10): 2111-2118.
35. Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012; 93 (1): 61-68.
36. Spinner ML, Saab G, Casabar E, Bowman LJ, Storch GA, Brennan DC. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation 2010; 90 (4): 412-418.
37. San Juan R, Yebra M, Lumbreras C, et al. A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients. Clin Transplant 2009; 23 (5): 666-671.
38. Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56 (6): 817-824.
39. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (4 Pt 1): 852-858.